Controversies in Hypertension V: Resistant and Refractory Hypertension.

[1]  A. Lother,et al.  Molecular pharmacology of mineralocorticoid receptor antagonists: the role of co-regulators , 2023, Steroids.

[2]  B. Pitt,et al.  Efficacy and Safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study , 2023, American journal of hypertension.

[3]  S. R. Thomas,et al.  Characterization of Individuals With Apparent Resistant Hypertension Using Contemporary Guidelines: Insights From CV-QUIC , 2023, Hypertension.

[4]  J. Václavík,et al.  A practical approach to assessment of non-adherence to antihypertensive treatment , 2023, Journal of hypertension.

[5]  J. Versmissen,et al.  Monitoring antihypertensive drug concentrations to determine nonadherence in hypertensive patients with or without a kidney transplant , 2023, Journal of hypertension.

[6]  Mark D. Huffman,et al.  Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis. , 2023, JAMA cardiology.

[7]  G. Filippatos,et al.  Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes , 2023, Clinical journal of the American Society of Nephrology : CJASN.

[8]  G. Naccarelli,et al.  A Subgroup Meta-Analysis Comparing the Renal Denervation Sham-Controlled Randomized Trials Among Those With Resistant and Nonresistant Hypertension. , 2023, The American journal of cardiology.

[9]  M. Vaduganathan,et al.  Nonsteroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease. , 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Deepak L. Bhatt,et al.  Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. , 2022, The New England journal of medicine.

[11]  G. Filippatos,et al.  A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease , 2022, Clinical kidney journal.

[12]  S. Oparil,et al.  An Update on Refractory Hypertension , 2022, Current Hypertension Reports.

[13]  G. Salles,et al.  Refractory Hypertension: a Narrative Systematic Review with Emphasis on Prognosis , 2022, Current Hypertension Reports.

[14]  F. Jaisser,et al.  Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics , 2021, Expert opinion on investigational drugs.

[15]  P. Wallemacq,et al.  Adherence to antihypertensive drug treatment in kidney transplant recipients , 2021, Blood pressure.

[16]  G. Filippatos,et al.  Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. , 2021, The New England journal of medicine.

[17]  P. Rossignol,et al.  Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER). , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[18]  G. Bakris,et al.  Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study , 2021, Hypertension.

[19]  V. Mordovin,et al.  Refractory and Resistant Hypertension in Patients with Type 2 Diabetes Mellitus: Different Response to Renal Denervation. , 2021, Kardiologiia.

[20]  S. Ito,et al.  Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[21]  Mahboob Rahman,et al.  Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort , 2020, Hypertension.

[22]  D. Bolignano,et al.  Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. , 2020, The Cochrane database of systematic reviews.

[23]  G. Bakris,et al.  Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine , 2020, European heart journal.

[24]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[25]  K. Kario,et al.  Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment‐resistant hypertension in high‐risk hypertension patients , 2020, Journal of clinical hypertension.

[26]  G. Salles,et al.  Refractory Hypertension and Risks of Adverse Cardiovascular Events and Mortality in Patients With Resistant Hypertension: A Prospective Cohort Study , 2020, Journal of the American Heart Association.

[27]  D. Cohen,et al.  Resistant Hypertension in People With CKD: A Review. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  P. Hopkins,et al.  The Unrecognized Prevalence of Primary Aldosteronism , 2020, Annals of Internal Medicine.

[29]  B. Williams,et al.  Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure , 2020, European journal of heart failure.

[30]  S. Oparil,et al.  Reserpine Substantially Lowers Blood Pressure in Patients with Refractory Hypertension: A Proof of Concept Study. , 2020, American journal of hypertension.

[31]  G. Parati,et al.  Medication adherence in hypertension. , 2019, Journal of hypertension.

[32]  S. Oparil,et al.  Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension , 2019, Hypertension.

[33]  L. Ruilope,et al.  Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. , 2019, Journal of hypertension.

[34]  B. Williams,et al.  Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial , 2019, The Lancet.

[35]  S. Ito,et al.  Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[36]  J. Montserrat,et al.  Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial , 2019, Journal of hypertension.

[37]  S. Ito,et al.  Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study , 2019, Journal of Human Hypertension.

[38]  P. Whelton,et al.  Prevalence of Apparent Treatment-Resistant Hypertension in the United States: Comparison of the 2008 and 2018 American Heart Association Scientific Statements on Resistant Hypertension , 2019, Hypertension.

[39]  S. Bornstein,et al.  Optimized Reference Intervals for Plasma Free Metanephrines in Patients With CKD. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  David A Calhoun,et al.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.

[41]  J. R. Nansseu,et al.  Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients , 2018, Heart.

[42]  S. Oparil,et al.  Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes , 2018, Hypertension.

[43]  S. Laurent,et al.  Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients , 2017, Journal of hypertension.

[44]  N. Samani,et al.  Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence , 2017, Hypertension.

[45]  J. Václavík,et al.  Heart rate is a useful marker of adherence to beta-blocker treatment in hypertension , 2017, Blood pressure.

[46]  N. Samani,et al.  Risk Factors for Nonadherence to Antihypertensive Treatment , 2017, Hypertension.

[47]  U. Martin,et al.  Detecting non-adherence by urine analysis in patients with uncontrolled hypertension: rates, reasons and reactions , 2017, Journal of Human Hypertension.

[48]  Y. Yamasaki,et al.  A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. , 2017, Journal of diabetes and its complications.

[49]  L. Smeeth,et al.  Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis , 2017, European journal of preventive cardiology.

[50]  S. Schmidt,et al.  [Aldosterone antagonists for preventing the progression of chronic kidney disease]. , 2016, Der Urologe. Ausg. A.

[51]  J. Staessen,et al.  Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension , 2016, Hypertension.

[52]  M. Hiligsmann,et al.  A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. , 2016, British journal of clinical pharmacology.

[53]  S. Oparil,et al.  Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. , 2016, Journal of the American Society of Hypertension : JASH.

[54]  E. Vicaut,et al.  Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. , 2016, Journal of the American College of Cardiology.

[55]  M. Uder,et al.  Adherence to Antihypertensive Medication in Treatment‐Resistant Hypertension Undergoing Renal Denervation , 2016, Journal of the American Heart Association.

[56]  I. Dasgupta,et al.  Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic , 2016, Journal of Human Hypertension.

[57]  A. Høieggen,et al.  Adherence to medication and drug monitoring in apparent treatment-resistant hypertension , 2016, Blood pressure.

[58]  M. Caulfield,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[59]  Khagendra Dahal,et al.  The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. , 2015, American journal of hypertension.

[60]  G. Bakris,et al.  The double challenge of resistant hypertension and chronic kidney disease , 2015, The Lancet.

[61]  B. Williams,et al.  Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation , 2015, Journal of Human Hypertension.

[62]  L. Ruilope,et al.  Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. , 2015, JAMA.

[63]  M. Burnier,et al.  Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis , 2015, Clinical Research in Cardiology.

[64]  C. Ayers,et al.  Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. , 2015, Journal of the American Society of Hypertension : JASH.

[65]  S. Oparil,et al.  Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. , 2015, Hypertension.

[66]  Q. Xiao,et al.  Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. , 2015, International journal of clinical and experimental medicine.

[67]  P. Muntner,et al.  Are two commonly used self-report questionnaires useful for identifying antihypertensive medication nonadherence? , 2015, Journal of hypertension.

[68]  Tushar Acharya,et al.  Resistant Hypertension and Associated Comorbidities in a Veterans Affairs Population , 2014, Journal of clinical hypertension.

[69]  M. Flather,et al.  Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. , 2014, European heart journal.

[70]  Yan-lu Xu,et al.  Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis , 2014, Journal of Human Hypertension.

[71]  F. Eitner,et al.  Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury , 2014, Journal of cardiovascular pharmacology.

[72]  S. Kjeldsen,et al.  Adjusted Drug Treatment Is Superior to Renal Sympathetic Denervation in Patients With True Treatment-Resistant Hypertension , 2014, Hypertension.

[73]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[74]  Nilesh J Samani,et al.  High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis , 2014, Heart.

[75]  C. Ayers,et al.  Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. , 2014, Journal of the American College of Cardiology.

[76]  D. Calhoun,et al.  Apparent and true resistant hypertension: definition, prevalence and outcomes , 2014, Journal of Human Hypertension.

[77]  T. Zelinka,et al.  Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis , 2013, Journal of hypertension.

[78]  V. Pavlik,et al.  Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. , 2013, Journal of the American Society of Hypertension : JASH.

[79]  R. Brook,et al.  Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network , 2013, Hypertension.

[80]  S. Kjeldsen,et al.  Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension After Witnessed Intake of Medication Before Qualifying Ambulatory Blood Pressure , 2013, Hypertension.

[81]  P. Ponikowski,et al.  Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial , 2013, European heart journal.

[82]  S. Toennes,et al.  Resistant hypertension? Assessment of adherence by toxicological urine analysis , 2013, Journal of hypertension.

[83]  J. Chudek,et al.  Resistant hypertension in visceral obesity. , 2012, European journal of internal medicine.

[84]  M. Heisler,et al.  Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss , 2012, BMC Health Services Research.

[85]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[86]  Nick Barber,et al.  Suitability of measures of self-reported medication adherence for routine clinical use: A systematic review , 2011, BMC medical research methodology.

[87]  G. Jean-Louis,et al.  Resistant Hypertension and Obstructive Sleep Apnea in the Primary-Care Setting , 2011, International journal of hypertension.

[88]  J. Banegas,et al.  Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring , 2011, Hypertension.

[89]  P. Sever,et al.  How common is true resistant hypertension? , 2011, Journal of Human Hypertension.

[90]  E. Muxfeldt,et al.  Prognostic influence of office and ambulatory blood pressures in resistant hypertension. , 2008, Archives of internal medicine.

[91]  S. Oparil,et al.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. , 2008, Archives of internal medicine.

[92]  S. Bangalore,et al.  Fixed-dose combinations improve medication compliance: a meta-analysis. , 2007, The American journal of medicine.

[93]  K. Chan,et al.  Methods for evaluation of medication adherence and persistence using automated databases , 2006, Pharmacoepidemiology and drug safety.

[94]  F. Cuccurullo,et al.  Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. , 2005, American journal of hypertension.

[95]  D. Calhoun,et al.  Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension , 2002, Hypertension.

[96]  S. Textor,et al.  Resistant Hypertension: Comparing Hemodynamic Management to Specialist Care , 2002, Hypertension.

[97]  M. Brown,et al.  Is resistant hypertension really resistant? , 2001, American journal of hypertension.

[98]  F. Magrini,et al.  High prevalence of cardiac and extracardiac target organ damage in refractory hypertension , 2001, Journal of hypertension.

[99]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[100]  L. Ruilope,et al.  Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. , 1998, Hypertension.

[101]  OUP accepted manuscript , 2021, European Heart Journal.

[102]  Akshay S. Desai,et al.  Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. , 2019, JACC. Heart failure.

[103]  K. Narkiewicz,et al.  Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. , 2015, Polskie Archiwum Medycyny Wewnetrznej.

[104]  George M. Savage,et al.  An Ingestible Sensor for Measuring Medication Adherence , 2015, IEEE Transactions on Biomedical Engineering.

[105]  J. Ceral,et al.  Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy , 2011, Hypertension Research.

[106]  A. Oliveras,et al.  Urinary albumin excretion is associated with true resistant hypertension , 2010, Journal of Human Hypertension.

[107]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .